The Preferred Global Oncology and Specialty Generics Partner
Latest news
- Lotus pharmaceuticals 3Q24 earnings call
- Lotus Pharmaceutical's novel drug Zepzelca® (lurbinectedin) has demonstrated significantly superior efficacy in First-line maintenance therapy for Small Cell Lung Cancer (ES-SCLC) when combined with Atezolizumab
- Lotus Reported Unaudited September Revenues of NT$1,187 million
About Lotus
Lotus is now a fast growing specialty generic company in Asia and also the largest pharma company in Taiwan. Our business model ensures competitive advantage through focused in-house capabilities and a network of partners for enhanced speed and flexibility. The company boasts a best in class R&D and manufacturing platform with headquarters in Taiwan.
Differentiated Portfolio
Lotus produces and promotes a unique portfolio of high quality and difficult-to-make pharmaceutical products fueling our growth. Lotus has more than 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US and has more than 250 products in the market.
Board of Directors
Lotus’ board of directors consists of eleven distinguished members with an exceptional knowledge and experience in the related fields to supervise the Company’s operation.
Leadership Team with Proven Track Record
Lotus’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of all stakeholders.